Previous findings suggest that physiological P2RY6 ligands and specific P2RY6 agonists can restore normal monocyte differentiation by restoring autophagy in some primary myeloid cells of patients with chronic granulocytic leukemia, demonstrating a potential link between P2RY6 and programmed cell death103. Here, P2RY6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.